The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10232 malaria professionals are enjoying the free benefits of MalariaWorld today

anti-malarial

Open Access | Schistosomiasis Coinfection in Children Influences Acquired Immune Response against Plasmodium falciparum Malaria Antigens

September 16, 2010 - 14:14 -- Kabogo Ndegwa
Author(s): 
Tamsir O. Diallo, Franck Remoue,Gilles Riveau,. et al
Reference: 
PLoS ONE 5(9): e12764

Our study suggests that schistosomiasis coinfection favours anti-malarial protective antibody responses, which could be associated with the regulation of IL-10 and IFN-γ production and seems to be antigen-dependent.

Medical Condition: 
Medical Treatment: 

Open Access | Extreme CD8 T Cell Requirements for Anti-Malarial Liver-Stage Immunity following Immunization with Radiation Attenuated Sporozoites

August 2, 2010 - 13:26 -- Patrick Sampao
Author(s): 
Nathan W. Schmidt, Noah S. Butler, Vladimir P. Badovinac, John T. Harty
Reference: 
PLoS Pathog 6(7): e1000998

Here, we used surrogate T cell activation markers to identify and track whole-parasite, RAS-vaccine-induced effector and memory CD8 T cell responses. Our data show that the differential susceptibility of RAS-immune inbred mouse strains to Plasmodium berghei or P. yoelii sporozoite challenge does not result from host- or parasite-specific decreases in the CD8 T cell response.

Medical Condition: 

Open Access | Pill characterization data streams for reducing exposure to inadequately identified anti-malarial medication in developing countries

July 26, 2010 - 13:53 -- Kabogo Ndegwa
Author(s): 
Pennefather P, Ahmad A, Crandall I, Suhanic W
Reference: 
Malaria Journal 2010, 9:214 (22 July 2010)

A system of this type would allow users to answer several questions. Is this medicine what it is supposed to be? Can it be used to treat locally encountered malaria?

Medical Condition: 
Medical Treatment: 

Natural immunization against malaria: causal prophylaxis with antibiotics

July 19, 2010 - 12:23 -- Kabogo Ndegwa
Author(s): 
J Friesen, O Silvie, ED Putrianti, JC Hafalla, K Matuschewski, S Borrmann
Reference: 
Sci Transl Med 14 July 2010, Vol. 2, Issue 40, p. 40ra49

Malaria remains the most prevalent vector-borne infectious disease and has the highest rates of fatality. Current antimalarial drug strategies cure malaria or prevent infections but lack a sustained public health impact because they fail to expedite the acquisition of protective immunity.

Medical Condition: 

Short Communication: Plasmodium vivax hypoxanthine-guanine phosphoribosyltransferase: A target for anti-malarial chemotherapy

July 19, 2010 - 10:31 -- Patrick Sampao
Author(s): 
Dianne T., Dana H., et al.
Reference: 
Molecular and Biochemical Parasitology, Volume 173, Issue 2, October 2010, Pages 165-169

We have purified the recombinant Pv 6-oxopurine (PRTase) and compared its properties with the human and Pf enzymes. The Pv enzyme uses hypoxanthine and guanine with similar catalytic efficiency to the Pf enzyme but xanthine is not a substrate, hence we identify this enzyme as PvHGPRT.

Medical Condition: 

Open Access | Extreme CD8 T Cell Requirements for Anti-Malarial Liver-Stage Immunity following Immunization with Radiation Attenuated Sporozoites

July 19, 2010 - 08:42 -- Kabogo Ndegwa
Author(s): 
Nathan W. Schmidt, Noah S. Butler, Vladimir P. Badovinac, John T. Harty
Reference: 
PLoS Pathog 6(7): e1000998

Radiation-attenuated Plasmodium sporozoites (RAS) are the only vaccine shown to induce sterilizing protection against malaria in both humans and rodents.

Medical Treatment: 

Dimeric cyclohexane-1,3-dione oximes inhibit wheat acetyl-CoA carboxylase and show anti-malarial activity

July 16, 2010 - 08:20 -- Kabogo Ndegwa
Author(s): 
Theola Louie, C. Dean Goodman, Georgina A. Holloway, Geoffrey I. McFadden, Vanessa Mollard, Keith G. Watson
Reference: 
Bioorganic & Medicinal Chemistry Letters, Volume 20, Issue 15, 1 August 2010, Pages 4611-4613

A series of dimeric 1,3-cyclohexanedione oxime ethers were synthesized and found to have significant antiplasmodial activity with IC50’s in the range 3–12 μM.

Medical Treatment: 

Open Access | Improvements in access to malaria treatment in Tanzania after switch to artemisinin combination therapy and the introduction of accredited drug dispensing outlets - a provider perspective

June 16, 2010 - 09:24 -- Kabogo Ndegwa
Tags: 
Author(s): 
Alba S, Hetzel MW, Goodman C, Dillip A, Liana J, Mshinda H, Lengeler C
Reference: 
Malaria Journal 2010, 9:164 (15 June 2010)

The public health and private retail sector are important complementary sources of treatment in rural Tanzania. Ensuring the availability of ALu in the private retail sector is important for its successful uptake.

Country: 
Medical Condition: 
Medical Treatment: 

Open Access | Atorvastatin as a potential anti-malarial drug: in vitro synergy in combinational therapy with quinine against Plasmodium falciparum

May 27, 2010 - 11:29 -- Patrick Sampao
Author(s): 
Parquet V, Henry M, Wurtz N, Dormoi J, Briolant S, Gil M, Baret E, Amalvict R, Rogier C, Pradines B
Reference: 
Malaria Journal 2010, 9:139 (25 May 2010)

Genotypes and gene copy number were assessed for pfcrt, pfmdr1, pfmdr2, pfmrp genes. In addition, the number of DNNND, DDNHNDNHNN repeats in pfnhe-1 ms4760 and the ms4760 profile were determined for each strains of P. falciparum.

Medical Condition: 

Open Access | In vitro and in vivo anti-malarial activity of Boerhavia elegans and Solanum surattense

May 13, 2010 - 14:27 -- Kabogo Ndegwa
Author(s): 
Ramazani A, Zakeri S, Sardari S, Khodakarim N, Djadid N
Reference: 
Malaria Journal 2010, 9:124 (12 May 2010)

Anti-plasmodial activities of extracts of B. elegans and S. surattense are reported for the first time.

Medical Treatment: 

Pages

Subscribe to RSS - anti-malarial